AI Governance in Life Sciences: What Regulators Expect in 2026
From the EU AI Act to FDA draft guidance on AI/ML, regulated companies face a new reality. Here's the practical governance framework you need — not the theoretical one consultants sell.
GxP Agents
AI Governance Practice · 2026-03-05
The conversation around AI governance in life sciences has shifted dramatically. It's no longer "should we govern AI?" — it's "how do we govern AI before the regulators tell us we're doing it wrong?"
The Regulatory Landscape Has Changed
Three forces converged in 2025-2026:
The EU AI Act classified certain life sciences AI applications as "high-risk," requiring conformity assessments, quality management systems, and post-market monitoring. If your AI touches patient safety, clinical decisions, or regulatory submissions — you're in scope.
FDA's draft guidance on AI/ML-enabled medical devices expanded beyond SaMD to include AI used in manufacturing, quality, and pharmacovigilance workflows. The message is clear: if AI influences GxP decisions, it needs governance.
ICH guidance continues to evolve, with Q2(R2) and emerging digital health guidelines acknowledging AI as part of the pharmaceutical quality system.
What a Real Governance Framework Looks Like
Forget the 40-page policy documents that sit in SharePoint. Effective AI governance in life sciences requires five operational capabilities:
1. AI Use Case Registry
Every AI application — from a simple classification model to a generative drafting assistant — needs to be inventoried with its risk classification, intended use, data sources, and human oversight controls.
2. Validation Strategy Aligned to Risk
Not every AI needs the same validation rigor. A risk-based approach (aligned with CSA thinking) means your deviation classifier gets a different validation path than your batch release prediction model.
3. Change Control for AI
Models drift. Data distributions shift. Prompts get updated. Your change control process needs to account for AI-specific changes that traditional software validation wasn't designed for.
4. Human-in-the-Loop Architecture
Every AI output that influences a GxP decision needs a defined human review point. Not as a checkbox — as an architected workflow step with clear accountability.
5. Audit Trail and Explainability
When an inspector asks "why did the AI recommend this?" you need an answer that traces from the model output back through the data, the logic, and the human decision that followed.
The Gap Between Theory and Practice
Most life sciences companies have AI governance policies. Few have AI governance operations. The difference?
GxP Agents was built for the operations side. Every agent in our platform operates within a governance framework that includes use case registration, human-in-the-loop controls, complete audit trails, and risk-appropriate validation.
Start Here
If you're building your AI governance program, start with three questions:
1. Do you know how many AI applications are running in your organization? (Most companies undercount by 3-5x when you include spreadsheet models, RPA bots, and embedded ML features.)
2. Can you trace any AI-influenced decision back to the model, the data, and the human who approved it? (If not, you have an audit risk.)
3. Does your change control system account for model updates, prompt changes, and training data shifts? (If not, you have a compliance risk.)
The companies that answer these questions now — before the next FDA inspection or EU AI Act enforcement action — will be the ones that turn AI governance from a cost center into a competitive advantage.